CGTX Profile
Cognition Therapeutics, Inc., headquartered in Purchase, New York, is a clinical-stage biopharmaceutical company specializing in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and central nervous system disorders. Founded in 2007, the company focuses on leveraging its expertise to address unmet medical needs in both neurodegenerative and retinal diseases, with a particular emphasis on conditions associated with aging.
The company’s lead product candidate, CT1812, is a sigma-2 receptor antagonist currently advancing through clinical trials. CT1812 is in Phase II trials for treating mild-to-moderate Alzheimer's disease and has completed Phase I trials for early-stage Alzheimer's disease. Additionally, it is undergoing Phase II trials for dementia with Lewy bodies (DLB) and preclinical trials for dry age-related macular degeneration (AMD). This broad clinical development program underscores the company's commitment to addressing a range of age-related cognitive and visual impairments.
In addition to CT1812, Cognition Therapeutics is developing CT2168, a therapeutic candidate targeting synucleinopathies, including DLB and Parkinson's disease. The company is also advancing CT2074, which aims to address dry AMD. These programs reflect Cognition’s strategic focus on developing novel treatments for complex diseases that currently lack effective therapies. The company’s approach involves innovative drug discovery and development techniques designed to enhance the understanding and management of these challenging conditions.
Cognition Therapeutics’ pipeline and research activities are indicative of its dedication to pioneering new therapeutic solutions for age-related diseases. By targeting key molecular pathways involved in neurodegenerative and retinal disorders, the company seeks to offer meaningful improvements in patient care and quality of life. As it continues to advance its clinical programs, Cognition Therapeutics remains at the forefront of biopharmaceutical innovation in the field of age-related disease treatment.
|
